GlassScriptPhysician profile
Renauld M Williams
NPI 1497119598
$1,112.05
in general payments reported to CMS, 2019-2025
20 companies · $615 in 2025
The $615 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.50 · 2022: $158 · 2023: $60.59 · 2024: $216 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $235.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $173.75 | 2022-2025 | Mounjaro, Kisunla, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $117.34 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.50 | 2021-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $83.25 | 2025 | Uptravi, Opsumit, Opsynvi |
| Novo Nordisk INC | $71.38 | 2021-2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $53.31 | 2022 | |
| Dexcom, INC. | $35.95 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $34.14 | 2025 | Vanta Adaptivestim |
| Globus Medical, INC. | $33.57 | 2025 | Senza |
| Impulse Dynamics (USA) INC. | $32.37 | 2025 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $27.48 | 2021-2025 | Airsupra |
| Biocomposites INC | $20.25 | 2024 | |
| Phadia US INC. | $19.24 | 2025 | Immunocap |
| Merck Sharp & Dohme LLC | $18.26 | 2025 | Verquvo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.00 | 2022 | |
| Amgen INC. | $14.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.53 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.40 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $12.28 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renauld Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.